Company

Cybin IRL

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 13, 2026 · PHASE 2 TRIAL

A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)

ClinicalTrials.gov

This is a Phase 2 proof-of-concept trial with completed enrollment but no results posted in this registry record; early-phase design and stated purpose to examine safety and preliminary efficacy support preliminary classification.

PreliminaryNCT06051721 Cybin IRL CYB004

Reported

Planned enrollment36

PhasePhase 2

Primary outcome measureHamilton Anxiety Rating Scale (HAM-A)

AUG 12, 2026 · PHASE 3 TRIAL

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

ClinicalTrials.gov

This is a Phase 3 registration with no posted results; the trial is actively recruiting and outcomes have not yet been reported.

PreliminaryCybin IRL CYB003 Depression Major Depressive Disorder

Reported

Estimated enrollment330

Primary outcome measureMontgomery-Asberg Depression Scale (MADRS)

Planned assessment timepointsScreening Day-45, Baseline, Day -1, Day 21,…

AUG 12, 2026 · PHASE 3 TRIAL

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

ClinicalTrials.gov

This is a Phase 3 trial registration with no posted results; the study is active but not recruiting, so outcomes remain unreported in this registry record.

PreliminaryCybin IRL CYB003 Major Depressive Disorder

Reported

Planned enrollment220

PhasePHASE3

Primary outcome measureMontgomery-Åsberg Depression Rating Scale (…